Immunocore Hits Enrollment Target in Kimmtrak Label Expansion Study

Immunocore IMCR announced that it has achieved target enrollment of 540 patients in the phase III TEBE-AM study, which is evaluating its sole marketed drug, Kimmtrak (tebentafusp), in patients with second-line or later advanced melanoma.

The randomized, registrational phase III TEBE-AM study is evaluating Kimmtrak as a monotherapy and in combination with Merck’s MRK blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab) versus investigator’s choice (control arm) in HLA-A*02:01-positive patients with advanced melanoma whose disease progressed after prior therapy.

Overall survival is the primary endpoint of the TEBE-AM study.

Merck’s biggest revenue driver, Keytruda, is approved for several cancer indications. MRK recorded $16.40 billion in Keytruda sales in the first half of 2026, up 4.2% year over year.

Immunocore expects to report top-line overall survival data from the TEBE-AM study as early as the end of 2026. If the study data are successful, they could provide meaningful visibility into Kimmtrak's potential in the previously treated advanced melanoma setting.

Per management, Kimmtrak could address a significant unmet need among up to 4,000 HLA-A*02:01-positive patients with previously treated advanced melanoma in the post-PD1 setting.

IMCR’s Price Performance

Year to date, shares of Immunocore have lost 6.4% against the industry’s increase of 5.8%.

Image Source: Zacks Investment Research

IMCR Thrives on Kimmtrak Sales Uptake

Kimmtrak is presently approved for treating patients with unresectable or metastatic uveal melanoma (mUM). Currently, Immunocore’s top line solely comprises worldwide net product sales of Kimmtrak. The drug has been witnessing strong demand.

Kimmtrak continues to generate solid sales growth globally. In the first half of 2026, Kimmtrak sales rose 16% year over year to $222.6 million. The strong commercial performance of Kimmtrak is expected to continue through the rest of 2026.

Since its approval and launch, Kimmtrak has established itself as the standard of care for eligible patients with metastatic uveal melanoma in most markets where it has been launched.

Kimmtrak continues to witness healthy adoption, supported by increasing physician awareness, broader reimbursement coverage and geographic expansion.

IMCR’s Zacks Rank & Stocks to Consider

Immunocore currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the biotech sector are Anika Therapeutics ANIK and Precigen PGEN, both sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, estimates for Anika Therapeutics’ 2026 bottom line have moved from a loss of 12 cents per share to earnings of $1.05 per share. Earnings estimates for 2027 have increased from 16 cents to 95 cents during the same time. ANIK’s shares have surged 120.5% year to date.

Anika Therapeutics’ earnings beat estimates in each of the trailing three quarters, with the average surprise being 950.00%.

Over the past 60 days, estimates for Precigen’s 2026 bottom line have moved from a loss of 2 cents per share to earnings of 25 cents. Earnings estimates for 2027 have increased from 25 cents to 86 cents during the same time. PGEN’s shares have rallied 63.9% year to date.

Precigen’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 108.96%.

7 Best Stocks for the Next 30 Days

Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."

Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention. 

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research